GlassScriptPhysician profile
Komal Masood
NPI 1295141455
$490.13
in general payments reported to CMS, 2019-2025
13 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.66 · 2022: $138 · 2023: $44.54 · 2024: $44.34 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $111.28 | 2022 | |
| Exact Sciences Corporation | $89.93 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $59.77 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $41.90 | 2025 | Rexulti |
| Novo Nordisk INC | $30.83 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $26.11 | 2019-2025 | Capvaxive, Gardasil 9 |
| Aimmune Therapeutics, INC. | $25.00 | 2023 | |
| Abbvie INC. | $22.42 | 2024 | |
| Shionogi INC | $19.54 | 2023 | Fetroja |
| Vanda Pharmaceuticals INC. | $19.00 | 2025 | Fanapt |
| Amgen INC. | $17.30 | 2025 | Otezla, Repatha |
| Insmed, INC. | $14.65 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.